<small id='y5akr'></small><noframes id='y5akr'>
<tbody id='y5akr'></tbody>
<bdo id='y5akr'></bdo><ul id='y5akr'></ul>
Zongertinib (BI 1810631) 獲中國NMPA藥(yao)品審評中心“突破性(xing)治(zhi)療”認定，用(yong)于(yu)治(zhi)療HER2突變的晚期、不(bu)可切除或(huo)轉移(yi)性(xing)非小細(xi)胞肺癌(NSCLC)成人患者(zhe)。勃(bo)林格殷格翰已啟動(dong)Beamion LUNG-2的Ⅲ期國際多中心臨床研究。(美通(tong)社)
<dd id='y5akr'><tbody id='y5akr'><td id='y5akr'><optgroup id='y5akr'><strong id='y5akr'></strong></optgroup><address id='y5akr'><ul id='y5akr'></ul></address><big id='y5akr'></big></td><table id='y5akr'></table></tbody><pre id='y5akr'></pre></dd><span id='y5akr'><b id='y5akr'></b></span>
<dfn id='y5akr'><optgroup id='y5akr'></optgroup></dfn><tfoot id='y5akr'><bdo id='y5akr'><div id='y5akr'></div><i id='y5akr'><dt id='y5akr'></dt></i></bdo></tfoot>
<ul id='y5akr'></ul>
<fieldset id='y5akr'></fieldset>
